title: [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
abstract: Turisteron proves to be a highly effective, poor in side effects, orally applicable estrogen preparation for the hormone therapy of the carcinoma of the prostate under the conditions of the routine practice. The cumulative 5-year survival rates of 197 patients observed of all categories of tumours (T1-4NxM0-1) were 66 +/- 10% and were depending upon the local growth of the tumour and upon the degree of metastasation between 81 +/- 18% and 47 +/- 42%. A discontinuation of the therapy due to strong side effects was necessary only in 4 cases (2.07%).
authors.forename: H M
authors.initials: HM
authors.lastname: Guddat
authors.forename: D
authors.initials: D
authors.lastname: Schnorr
authors.forename: F
authors.initials: F
authors.lastname: Zemke
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: C025723:ethinyl estradiol sulfonate; D004997:Ethinyl Estradiol
vernacular_title: Erste Ergebnisse der multizentrischen klinischen Prüfung Stufe IV von Turisteron zur Therapie des Prostatakarzinoms.